Department of Otolaryngology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia.
Transl Res. 2022 Oct;248:87-110. doi: 10.1016/j.trsl.2022.05.002. Epub 2022 May 18.
Adeno-associated viruses (AAVs) represent some of the most commonly employed vectors for targeted gene delivery and their extensive study has resulted in the approval of multiple gene therapies to treat human diseases. The intranasal route of vector application in gene therapy offers several advantages over traditional ways of administration. In addition to targeting local tissue like the olfactory epithelium, it provides minimally invasive access to various organ systems, including the central nervous system and the respiratory tract. Through a systematic literature review, a total of 53 articles that investigated the intranasal application of AAVs were identified, included, and summarized in this manuscript. Within these studies, AAV-based gene therapy was mainly investigated for its application in various infectious, pulmonary, or neurologic and/or psychiatric diseases. This review gives a comprehensive overview of the current technological state of the art regarding the intranasal application of AAVs for gene transfer and discusses remaining hurdles, which still have to be resolved before this approach can effectively be implemented in the routine clinical setting.
腺相关病毒 (AAV) 是靶向基因传递最常用的载体之一,对其的广泛研究促成了多种基因治疗药物的获批,以治疗人类疾病。与传统的给药途径相比,基因治疗中应用载体的鼻腔给药途径具有多种优势。除了靶向嗅觉上皮等局部组织外,它还可以微创进入包括中枢神经系统和呼吸道在内的各种器官系统。通过系统的文献回顾,共确定了 53 篇研究 AAV 鼻腔应用的文章,这些文章被纳入并总结在本手稿中。在这些研究中,基于 AAV 的基因治疗主要针对其在各种传染性、肺部或神经和/或精神疾病中的应用进行了研究。本综述全面概述了 AAV 鼻腔应用于基因传递的当前技术现状,并讨论了仍需解决的障碍,在该方法能够有效地常规临床应用之前,这些障碍仍需解决。